Business Wire

Deel, the Leading Platform for Global Hiring and Payments, Acquires Zeitgold to Strengthen Payroll & AI Offerings

Share

Deel, the market leader in the global payroll and compliance space, announced today that it had joined forces with Zeitgold to fuel international growth and enhance the depth and breadth of its product offerings. This acquisition marks a significant milestone for Deel as the company continues to scale, adding thousands of customers as working and hiring practices continue to transform rapidly. Deel is adding a full line of products through this acquisition to improve their customer experience further and provide them with the right solutions to scale internationally.

Deel enables businesses to hire anyone, anywhere, in a compliant manner. With Deel, hiring and onboarding international employees or contractors takes under 5 minutes, with no local entity required. Businesses can also pay their teams in 120+ currencies with just a click. In April 2021, Deel raised $156 million in Series C funding at a $1.25 billion valuation. With their new funding, Deel announced plans to continue international expansion, grow its team through mergers & acquisitions, hire exceptional talent globally, all while improving, building, and expanding its product offerings. The purchase of Zeitgold marks the first step in the company’s extensive M&A plans and reinforces its global payroll offering.

Zeitgold was founded in 2015 by Jan Deepen and Stefan Jeschonnek, co-founders of SumUp, the European fintech unicorn, and Kobi Eldar, a former senior intelligence officer of the prestigious 8200 Israeli unit. Zeitgold has raised over $60M from leading venture capital firms such as Battery Ventures, Vintage Investment Partners, HV Holtzbrinck Ventures, as well as insurance company AXA and Deutsche Bank. All existing Zeitgold investors will now be joining Deel as shareholders.

Zeitgold offers AI-powered payroll and automated bookkeeping software for businesses and contractors. The contractor product assists thousands of independent contractors with their setup, bookkeeping, and tax filing. Zeitgold’s highly skilled team and impressive track record have made it a gem of the German technology industry. With this purchase, Deel is adding senior leadership to its ranks and gains the expertise of Zeitgold’s team in global payroll, automation, and AI. The deal also provides valuable IP in global payroll processing based on a powerful workflow engine and document understanding AI stack, which Deel will leverage to scale up and serve hundreds of thousands of clients.

"With the addition of Zeitgold, we'll accelerate even faster and reinforce our European leadership," said Deel CEO Alex Bouaziz. "We're taking Zeitgold's best-in-class engine and plugging it into the core of our platform to help Deel supercharge its product offerings."

"By joining forces with Deel, we can leverage our core technology and products at a global scale," said Zeitgold CEO Jan Deepen. "The new capabilities we're bringing to Deel will allow contractors and employees all over the world to stay compliant and take care of their payroll with confidence, all while continuing to help reduce hiring barriers worldwide."

Deel was co-founded in 2018 by MIT alumni Bouaziz and Wang. The founders set out to solve a problem that most businesses worldwide found daunting—the ability to hire people from anywhere easily. In the past 12 months, the company grew by more than 1000% in revenue to support over 3,000 businesses worldwide. It has plans to set up 100 new Deel-owned entities across the world by the end of 2021. With the acquisition of Zeitgold, Deel plans to deploy this offering into every country where it operates, shattering hiring barriers worldwide.

About Deel

Deel is a global compliance and payroll solution that helps businesses hire anyone, anywhere. Using a tech-enabled self-serve process, companies can now hire independent contractors and full-time employees in over 150 countries, compliantly and in minutes. Deel enables any business to compliantly create, sign, and send localized contracts from a library of templates. Deel automates the process of collecting country-specific documents like tax documents from contractors and employees to ensure they get set up to work correctly. The platform also allows companies to pay international contractors and employees in more than 120 currencies with just a few clicks. Learn more about Deel here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lisa Tarter
lisa@tidalwavepr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 09:42:00 EET | Press release

Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable

GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 09:30:00 EET | Press release

Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus

Hisense Joins HEVC Advance Patent Pool22.12.2025 04:06:00 EET | Press release

Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye